Summarizing the incidence of adverse events using volcano plots and time intervals

Clinical Trials

Volumn 10, Issue 3, 2013, Pages 398-406

  Zink, Richard C ^a   Wolfinger, Russell D ^a   Mann, Geoffrey ^a  

^a SAS INSTITUTE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICARDIPINE; PLACEBO;

ADVERSE DRUG REACTION; AGITATION; ANEMIA; ANOXIA; ARTICLE; ATELECTASIS; BRAIN EDEMA; BRAIN HEMORRHAGE; CELLULITIS; DELIRIUM; DRUG OVERDOSE; EMPHYSEMA; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FLUTTER; HEART BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; HEMATURIA; HUMAN; HYPERNATREMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INCIDENCE; ISOSTHENURIA; LUNG EDEMA; MENINGITIS; PARANOIA; PHLEBITIS; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; SIDE EFFECT; SINUS BRADYCARDIA; STATISTICAL ANALYSIS; SUBARACHNOID HEMORRHAGE; T WAVE INVERSION; THROMBOCYTE LYSIS; TIME SERIES ANALYSIS; VASOCONSTRICTION; VOMITING;

CLINICAL TRIALS AS TOPIC; COMPUTER GRAPHICS; DATA INTERPRETATION, STATISTICAL; HUMANS; INCIDENCE; RISK ASSESSMENT; SUBARACHNOID HEMORRHAGE; THERAPEUTICS;

EID: 84878261354     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513485311     Document Type: Article

References (8)

1. Haley EC, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1993 ; 78: 537-47
2. Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharm Stat. 2008 ; 7: 20-35
3. Stokes ME, Davis CS, Koch GG Categorical Data Analysis Using the SAS®System. 3 rd edn). SAS Institute, Inc., Cary, NC, 2012. Cary, NC: SAS Institute, Inc. ; 2012 :
4. Jin W, Riley RM, Wolfinger RD, et al. The contributions of sex, genotype and age to transcriptional variance in Drosophila melanogaster. Nat Genet. 2001 ; 29: 389-95
5. Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: A report of the safety planning, evaluation, and reporting team. Clin Trials. 2009 ; 6: 430-40
6. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B. 1995 ; 57: 289-300
7. Mehrotra DV, Heyse JF. Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res. 2004 ; 13: 227-38
8. Mehrotra DV, Adewale AJ. Flagging clinical adverse experiences: Reducing false discoveries without materially compromising power for detecting true signals. Stat Med. 2012 ; 31: 1918-30